Aplisol®

How To Administer, Read & Interpret 1,2




* For persons who are otherwise at low risk for TB and who are tested at the start of employment, a reaction of ≥ 15 mm is considered positive.

1 CDC. Mantoux Tuberculin Skin Test. Facilitator Guide. Available at http://www.cdc.gov/tb/education/mantoux/guide.htm. November 2013. Accessed April 7, 2015

2 Aplisol [package insert]. Spring Valley, NY: Par Pharmaceutical Companies; 2014.

Important Safety Information

Aplisol® is contraindicated in patients with known hypersensitivity or allergy to Aplisol® or any of its components. Aplisol® should not be administered to persons who have previously experienced a severe reaction to tuberculin purified protein derivative (e.g., vesiculation, ulceration, or necrosis) because of the severity of reaction that may occur at the test site. Strongly positive test reactions may result in scarring at the test site. Immediate erythematous or other reactions may occur at the injection site. Systemic allergic reactions including anaphylaxis/anaphylactoid reactions have been reported to occur in association with the use of Aplisol®. Several factors, such as certain types of infections, corticosteroids and immunosuppressants, malnutrition, and other various disease states and conditions have been reported to alter the ability to respond to the tuberculin test. A review of the patient's history with respect to possible immediate type hypersensitivity to the product, determination of previous use of Aplisol®, the presence of any contraindication, as well as potential factors that may alter results should be thoroughly conducted.

View the full Prescribing Information for Aplisol®

For more information about Par Sterile Products, please Contact Us.